Latest Content

The combination of sacituzumab with pembrolizumab did not lead to a decline in physical functioning or quality of life in patients with metastatic TNBC.

Buparlisib combined with paclitaxel failed to improve overall survival vs paclitaxel alone for patients with PD-1/PD-L1–pretreated HNSCC.

Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases to become chronic.

Adding zabilugene almadenorepvec to SOC chemotherapy and nab-paclitaxel was safe and effective in patients with metastatic pancreatic ductal adenocarcinoma.

Ivonescimab plus chemotherapy improved progression-free survival and response rates with manageable safety vs tislelizumab in advanced squamous NSCLC.

The DESTINY-Breast11 trial found neoadjuvant T-DXd followed by THP improved pathologic complete response vs ddAC-THP in high-risk, HER2-positive early breast cancer.

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI alone in HR+, HER2– early breast cancer.

Adding perioperative durvalumab to neoadjuvant chemotherapy did not worsen health-related quality of life for patients with muscle-invasive bladder cancer.

A preliminary analysis of a prospective study of patients with solid tumors identified subgroups at risk of depressive symptoms via patient-report outcomes.

Patient-reported outcomes showed that health-related QOL stayed at baseline for patients with HRRM-positive mHSPC receiving a niraparib regimen.

Chemo-induced myelosuppression can affect patients’ ability to do daily tasks, and management varies by patient, treatment regimens, locations, and more.

The addition of navtemadlin to ruxolitinib for JAK inhibitor-naive patients with myelofibrosis with suboptimal response to ruxolitinib will be evaluated in the phase 3 POIESIS trial.

On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age of immunotherapy.